Acquiring Company
BioGen
Acquired Company
Apellis Pharmaceuticals
CambridgeWalthamBiotechnologyHealth CareBiotechnology ResearchBiotechnologyHealthcareHealth CareTherapeuticsPharmaceuticalBiopharmaDescription
Biogen has agreed to acquire Apellis Pharmaceuticals for approximately $5.6 billion, priced at $41 per share in cash. The deal includes contingent value rights for Apellis investors, tied to the sales benchmarks of their leading drug, Syfovre. This acquisition is part of Biogen's strategy to expand its portfolio in immunology and rare diseases.
Quick answer
BioGen is acquiring Apellis Pharmaceuticals for $5.6 billion, announced April 1, 2026. BioGen is based in Cambridge, Massachusetts, United States.
- How much did BioGen pay for Apellis Pharmaceuticals?
- The reported deal value is $5.6 billion.
- What does BioGen do?
- BioGen is a biotechnology company specializing in the development of therapies for neurological diseases.
- Where are BioGen and Apellis Pharmaceuticals based?
- BioGen is based in Cambridge, Massachusetts, United States. Apellis Pharmaceuticals is based in Waltham, Massachusetts, United States.
- Who are the decision-makers at BioGen?
- Fundz holds 1 contact at BioGen. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Other recent acquisitions in Biotechnology Research and Healthcare
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- Aurinia acquires Kezar Life Sciences for $6.955/share (March 30, 2026)
- ESTEVE acquires TerSera's Infusion Business Unit (May 4, 2026)
- Eli Lilly to acquire Ajax Therapeutics for $2.3B, $2.3B (April 27, 2026)
- Cyclerion to merge with Korsana Biosciences (April 1, 2026)
- Eli Lilly to acquire Centessa Pharmaceuticals (March 31, 2026)
- Merck to acquire Terns Pharmaceuticals for $6.7B, $6.7B (March 25, 2026)
Who to call at BioGen, and when
When BioGen changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day BioGen raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at BioGen, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at BioGen. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment BioGen makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Apellis Pharmaceuticals?
Apellis Pharmaceuticals was acquired by BioGen, based in Cambridge. The deal was reported on April 1, 2026. BioGen is a biotechnology company specializing in the development of therapies for neurological diseases. It has pioneered innovations in treatment for various neurodegenerative conditions. BioGen is publicly traded (BIIB) and operates in Biotechnology.
When did BioGen acquire Apellis Pharmaceuticals?
BioGen's acquisition of Apellis Pharmaceuticals was reported on April 1, 2026. Biogen has agreed to acquire Apellis Pharmaceuticals for approximately $5.6 billion, priced at $41 per share in cash. The deal includes contingent value rights for Apellis investors, tied to the sales benchmarks of their leading drug, Syfovre. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Apellis Pharmaceuticals do?
Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that combines courageous science and compassion to develop life-changing therapies for some of the most challenging diseases patients face. It is privately held, operating in Biotechnology, and is based in Waltham.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.